ABX · Abacus Global Management, Inc.

The thesis

Abacus Global Management is shifting from one-off gains on life insurance policies toward recurring management fees, but the shares are still more likely to lag the S&P 500 than lead it. The third-quarter report, expected around 5 November 2026 (date not yet confirmed by the company), settles whether adjusted earnings turn into reported profit.

The adjusted close was $8.36 on 27 October 2026, up from $7.73 on 14 October 2026 but 30.3% below the adjusted 52-week high of $12.00 and down 20.2% over three months, per split- and dividend-adjusted daily closes. The 14-day relative strength index (RSI) was 51.7, a neutral reading after 34.1 on 14 October 2026. The shares remain below the 18 September 2026 adjusted close of $8.77.

New since the last note: Piper Sandler kept its Neutral rating on 19 October 2026 and lowered its price target to $10, according to a company-news headline. Its July target was $13. The narrative is maturing: the buyback, securitization and founder releases are well known, and the price has recovered only part of the September-October decline.

Bullish and bearish views on Abacus Global Management, Inc.

The bull case on Abacus Global Management, Inc. (ABX), in brief: Buyback authorization is large. The bear case: Analyst target moved down.

Bull case

• Buyback authorization is large. The 13 August 2026 release authorized $100 million of repurchases starting 17 August 2026, funded by free cash flow, balance-sheet transaction proceeds and cash on hand. The board noted $80 million repurchased since December 2023.
• Securitization widens the funding base. The 25 September 2026 release describes a securitization of more than $400 million backed by life insurance policies, upsized on demand, with investment-grade Class A and Class B notes.
• Fee-capital formation is running. Second-quarter 2026 revenue was a record $73.0 million, up 30% from a year earlier, and longevity funds raised $544.2 million in the first half, per the 6 August 2026 results.
• Founders dropped planned sales. On 23 September 2026 the three founders ended their Rule 10b5-1 plans (pre-arranged selling schedules), per the company release.
• Distribution partnership added. The 13 October 2026 release announced Abacus LifeARC will be integrated into the Retirable retirement-planning platform.

Bear case

• Analyst target moved down. Piper Sandler lowered its target to $10 on 19 October 2026 and stayed at Neutral. MarketBeat's $12.00 average target for five analysts is dated 26 September 2026, before that cut.
• The FY2026 adjusted EPS guide of $1.00–$1.05 rests on the adjusted measure.
• Founders are leaving daily roles. The 23 September 2026 release says Sean McNealy, Matthew Ganovsky and Scott Kirby are transitioning from day-to-day operating duties.
• Valuation method changed. The company disclosed on 24 August 2026 that policy carrying values moved to the Historical Return Method effective Q2 2026. Carrying values rest on actuarial mortality assumptions.
• Price lags the news. The adjusted close was $8.77 on 18 September 2026 and $8.36 on 27 October 2026, across the buyback, securitization, founder and Retirable releases.

Price setup

The adjusted close of $8.36 on 27 October 2026 sits between the 14 October 2026 close of $7.73 and the 18 September 2026 close of $8.77. The $8.77 close is the nearest prior high the shares would need to regain to reverse the September decline. The 52-week high of $12.00 is adjusted; the raw July high printed $12.44.

Crowding evidence is thin on the buying side. No heavy retail attention, share issuance into strength or insider selling is documented since 23 September 2026. The imminent earnings date is the main crowding item: the shares will move on the Q3 print against the $0.26–$0.28 adjusted EPS guide.

Catalysts, next 30 days

• 31 December 2026: on-chain target. The company's target for the balance-sheet portfolio to be tokenized (recorded on a blockchain). No named custody partner or revenue line had been disclosed at the last review.

Elapsed catalysts

• ~5 November 2026, est.: Q3 2026 results. The company guided adjusted EPS of $0.26–$0.28. The prior-year Q3 report came on 6 November 2025 per TipRanks, and the 2026 date is unconfirmed. (passed 1d ago)
• Around the report: buyback usage. The report should show how much stock was repurchased since the program started on 17 August 2026. (passed 81d ago)

What would change the view

The case breaks if Q3 adjusted EPS comes in under the $0.26–$0.28 guide or the $1.00–$1.05 FY2026 range is cut. It also breaks if GAAP EPS stays near the Q2 level of $0.07 while the adjusted figure carries the story. Fee-capital inflows below the $544.2 million raised in the first half would weaken the recurring-fee argument. A named management change in an 8-K, or new Form 4 or Form 144 filings by officers or directors, would add to the bear case.

A daily close below $7.25, under the 14 October 2026 close of $7.73, ends the case on price. A recovery above the $8.77 close of 18 September 2026, with a Q3 print that meets the guide, would move the read toward even odds.

What it trades with

Abacus trades on its own earnings quality and the valuation of life settlement policies, which is a niche with few listed peers. No current theme cluster carries the name. Moves in the shares track company releases and the adjusted-versus-GAAP debate more than index direction. The ticker also collides with Barrick's legacy symbol, so headlines about Barrick Mining dated 19 October to 23 October 2026 do not concern Abacus.